SCHEMBL3935893

SCHEMBL3935893

Cc1ccc(S(=O)(=O)n2c(-c3ccccc3)c(OCCN(C)C)c3cc(Br)cc(Br)c32)c(Br)c1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACLY P53396 2/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C19 P33261 1/20 0.34
KDM4E B2RXH2 9/20 0.34
ALDH1A1 P00352 7/20 0.33
TDP1 Q9NUW8 2/20 0.33
MAOB P27338 1/20 0.33
LMNA P02545 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
HTR7 P34969 2/20 0.32
NPY1R P25929 1/20 0.32
NPY2R P49146 1/20 0.32
ACVR1 Q04771 1/20 0.31
TACR3 P29371 2/20 0.31
KCNH2 Q12809 1/20 0.31
SIGMAR1 Q99720 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562490 0.91 ACLY (0.35) ACLYCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL3567877 0.91 HTR7 (0.37) ACLYCYP1A2CYP2D6KDM4EALDH1A1
SCHEMBL3561713 0.90 HTR6 (0.37) ACLYKDM4EALDH1A1LMNAHTR7
SCHEMBL3555633 0.89 AGTR1 (0.39) ACLYCYP1A2CYP2D6KDM4EALDH1A1
SCHEMBL3555537 0.88 ACLY (0.38) ACLYCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL3558071 0.87 ACLY (0.37) ACLYCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL3559969 0.87 HTR6 (0.37) CYP1A2CYP2D6KDM4EALDH1A1LMNA
SCHEMBL3563867 0.87 CYP1A2 (0.38) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL3929367 0.86 AGTR1 (0.39) ACLYCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL3562280 0.85 CHRM2 (0.36) KDM4EALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP claimed
US-7507835-B2 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD. (IN) 2009-03-24 US claimed
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2006-08-03 US claimed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP claimed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO claimed
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP disclosed
US-7507835-B2 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD. (IN) 2009-03-24 US disclosed
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT ACLY 4542/4885CYP1A2 52/4885CYP2D6 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.